Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $17.95 million. The enterprise value is $86.48 million.
| Market Cap | 17.95M |
| Enterprise Value | 86.48M |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 28.95 million shares outstanding. The number of shares has increased by 16.94% in one year.
| Current Share Class | 28.95M |
| Shares Outstanding | 28.95M |
| Shares Change (YoY) | +16.94% |
| Shares Change (QoQ) | +8.00% |
| Owned by Insiders (%) | 12.24% |
| Owned by Institutions (%) | 13.13% |
| Float | 18.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.93% |
| Return on Invested Capital (ROIC) | -153.63% |
| Return on Capital Employed (ROCE) | -221.05% |
| Weighted Average Cost of Capital (WACC) | 7.09% |
| Revenue Per Employee | $230,870 |
| Profits Per Employee | -$798,261 |
| Employee Count | 115 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 6.71 |
Taxes
In the past 12 months, Celularity has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.02% in the last 52 weeks. The beta is 0.48, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -67.02% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 32.86 |
| Average Volume (20 Days) | 154,781 |
Short Selling Information
The latest short interest is 345,339, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 345,339 |
| Short Previous Month | 373,196 |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
In the last 12 months, Celularity had revenue of $26.55 million and -$91.80 million in losses. Loss per share was -$3.59.
| Revenue | 26.55M |
| Gross Profit | 6.48M |
| Operating Income | -59.40M |
| Pretax Income | -91.71M |
| Net Income | -91.80M |
| EBITDA | -54.01M |
| EBIT | -59.40M |
| Loss Per Share | -$3.59 |
Balance Sheet
The company has $6.18 million in cash and $74.71 million in debt, with a net cash position of -$68.54 million or -$2.37 per share.
| Cash & Cash Equivalents | 6.18M |
| Total Debt | 74.71M |
| Net Cash | -68.54M |
| Net Cash Per Share | -$2.37 |
| Equity (Book Value) | -37.76M |
| Book Value Per Share | -1.32 |
| Working Capital | -68.14M |
Cash Flow
| Operating Cash Flow | -13.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.38M |
| Net Borrowing | 10.79M |
| Free Cash Flow | -13.25M |
| FCF Per Share | -$0.46 |
Margins
| Gross Margin | 24.39% |
| Operating Margin | -223.72% |
| Pretax Margin | -345.44% |
| Profit Margin | n/a |
| EBITDA Margin | -203.44% |
| EBIT Margin | -223.72% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.94% |
| Shareholder Yield | -16.94% |
| Earnings Yield | -511.52% |
| FCF Yield | -73.85% |
Analyst Forecast
The average price target for Celularity is $25.00, which is 3,932.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.00 |
| Price Target Difference | 3,932.26% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 157.40% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -15.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.06 |
| Piotroski F-Score | 2 |